08/15/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/15/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the SalivaDirect assay. The SalivaDirect assay is authorized for use with saliva specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
08/14/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/14/2020. This web page provides information and documents about the Food and Drug Administration's issuing of Emergency Use Authorizations (EUAs) for certain personal protective equipment products, including face shields, other barriers, and respiratory protective devices such as respirators, during the COVID-19 pandemic. (Text)
08/13/2020 12:00 AM EDT
Source: World Health Organization, Pan American Health Organization (PAHO). Published: 8/13/2020. This eight-page document details how the Pan American Health Organization/World Health Organization (PAHO/WHO) requests that Member States intensify efforts to ensure access to prenatal care services, as well as to implement preventive measures to reduce morbidity and mortality associated with COVID-19 across all levels of the health system, in order to maintain the commitment to reducing maternal and perinatal mortality and the progress achieved to date. (PDF)
08/13/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/13/2020. This six-page fact sheet informs healthcare providers about REGIOCIT, which has been authorized for emergency use as a replacement solution in adult patients treated with Continuous Renal Replacement Therapy (CRRT), and for whom RCA is appropriate, during the COVID-19 pandemic. (PDF)
08/13/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/13/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of a Molecular LDT COVID-19 Authorized Test called the Pro-AmpRT SARS-CoV-2 Test that has been issued an Emergency Use Authorization (EUA) by the FDA. The Molecular LDT COVID-19 Authorized Test is authorized for use on certain respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
08/13/2020 12:00 AM EDT
Source: Brookings Institution. Published: 8/13/2020. This report uses a novel panel data set collected between March and July of 2020 to describe disparities in outcomes related to the COVID-19 pandemic across race/ethnicity and employment status. The evidence suggests a need for a more robust safety net, such as an expanded unemployment benefits program and more accessible public health insurance during the COVID-19 pandemic, as well as more deliberate targeting of federal support to Black and Hispanic households. (Text)
08/12/2020 12:00 AM EDT
Source: American Academy of Pediatrics (AAP). Published: 8/12/2020. This guidance was developed to help pediatric practices determine when to test for severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection in their patient population. (Text)
08/12/2020 12:00 AM EDT
Source: American Academy of Pediatrics (AAP). Published: 8/12/2020. This web page provides guidance for mitigating the risk of infection for all who work or receive care in pediatric ambulatory settings, including the appropriate use of personal protective equipment (PPE) along with consistent and effective infection prevention and control practices. (Text)
08/11/2020 12:00 AM EDT
Source: Center for Health Care Strategies, Inc. (CHCS). Published: 8/11/2020. This one-hour, 31-minute webinar highlights the experiences and innovations of three medical respite centers in California and Washington State during COVID-19. Presenters provide an overview of programs and share how their medical respite centers responded to COVID-19, including changes to structures, processes, and partners, as well as lessons for how to improve their services for people experiencing homelessness. (Video or Multimedia)
08/11/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/11/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the LumiraDx SARS-CoV-2 RNA STAR. The LumiraDx SARS-CoV-2 RNA STAR test is authorized for use with respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
08/11/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/11/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Biomeme SARS-CoV-2 Real-Time RT-PCR Test. The Biomeme SARS-CoV-2 Real-Time RT-PCR Test is authorized for use with respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
08/11/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/11/2020. This web page provides information on importing certain medical devices during the COVID-19 pandemic. It describes procedures for importing devices that have been issued Emergency Use Authorizations (EUAs) and for devices for which an enforcement discretion policy has been published in guidance. (Text)
08/11/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/11/2020. This web page provides information for medical device establishments, including owners and operators of places of business (also called facilities) that are involved in the production (e.g., manufacturing, assembling, or processing) and distribution of medical devices that are authorized by Emergency Use Authorizations (EUAs) or that are the subject of one of FDA’s COVID-19 guidance documents. (Text)
08/11/2020 12:00 AM EDT
Source: Center for Strategic and International Studies (CSIS). Published: 8/11/2020. This one-hour video features a discussion on the ACT Accelerator’s COVAX Facility. COVAX has emerged as a promising, nascent, international initiative to develop and equitably distribute COVID-19 vaccines to benefit all countries. (Video or Multimedia)
08/10/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/10/2020. This two-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Prismaflex HF20 Set to provide continuous renal replacement therapy (CRRT) to treat low weight (8-20 kg) and low blood volume patients who have acute renal failure, fluid overload, or both, and who cannot tolerate a larger extracorporeal circuit volume in an acute care environment during the COVID-19 pandemic. (PDF)
08/10/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/10/2020. This three-page fact sheet informs healthcare providers of the emergency use of a Molecular LDT COVID-19 Authorized Test called the Solaris Multiplex SARS-CoV-2 Assay that has been issued an Emergency Use Authorization (EUA) by the FDA. The Molecular LDT COVID-19 Authorized Test is authorized for use on certain respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
08/10/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/10/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of a Molecular LDT COVID-19 Authorized Test called the Alpha Genomix TaqPath SARS-CoV-2 Combo Assay that has been issued an Emergency Use Authorization (EUA) by the FDA. The Molecular LDT COVID-19 Authorized Test is authorized for use on certain respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
08/08/2020 12:00 AM EDT
Source: Infectious Diseases Society of America (IDSA). Published: 8/8/2020. This one-hour webinar features speakers who discuss neurologic manifestations in patients with COVID-19, what is known and not known about the neurology of COVID-19, and several case scenarios. (Video or Multimedia)
08/07/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/7/2020. This three-page fact sheet informs healthcare providers of the emergency use of a Molecular LDT COVID-19 Authorized Test called the GWU COVID-19 RT-PCR Test that has been issued an Emergency Use Authorization (EUA) by the FDA. The Molecular LDT COVID-19 Authorized Test is authorized for use on certain respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
08/07/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/7/2020. This three-page memorandum was written in response to a stakeholder request to extend the manufacturer labeled expiration date of five (5) lots of doxycycline hyclate 100 mg capsules manufactured by West-Ward Pharmaceuticals (West-Ward) that have been stockpiled for anthrax preparedness under the manufacturer labeled storage conditions. (PDF)
08/06/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/6/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of a Molecular LDT COVID-19 Authorized Test called the Helix COVID-19 NGS Test that has been issued an Emergency Use Authorization (EUA) by the FDA. The Molecular LDT COVID-19 Authorized Test is authorized for use on certain respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
08/06/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/6/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the VIDAS® SARS-COV-2 IgM. The VIDAS® SARS-COV-2 IgM is authorized for the detection of antibodies to SARS-CoV-2 in human serum or plasma (lithium heparin). (PDF)
08/06/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/6/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the VIDAS® SARS-COV-2 IgG. The VIDAS® SARS-COV-2 IgG is authorized for the detection of antibodies to SARS-CoV-2 in human serum or plasma (lithium heparin). (PDF)
08/06/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention (CDC). Published: 8/6/2020. This one-hour, 19-minute webinar presents information about respiratory protection resources in long-term care during the COVID-19 pandemic. Speakers define "respirator," discuss the hierarchy of controls, and discuss hazard assessment criteria. (Video or Multimedia)
08/05/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/5/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the ViroKey™ SARS-CoV-2 RT-PCR Test. The ViroKey™ SARS-CoV-2 RT-PCR Test is authorized for use with certain respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
08/05/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/5/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the WANTAI SARS-CoV-2 Ab ELISA. The WANTAI SARS-CoV-2 Ab ELISA is authorized for the detection of total antibodies to SARS-CoV-2 inhuman serum and Acid Citrate Dextrose (ACD) plasma. (PDF)
08/05/2020 12:00 AM EDT
Source: Government of Canada. Published: 8/5/2020. This web page provides guidance for the delivery of seasonal influenza vaccine in fall 2020, when ongoing COVID-19 activity may continue to stress public health capacity and affect clinic operations and attendance. (Text)
08/01/2020 12:00 AM EDT
Source: National Emerging Special Pathogens Training and Education Center (NETEC). Published: 8/2020. The resources on this web page reflect the current supply shortage in which masks, goggles, and face shields may be conserved during the COVID-19 pandemic. Flyers, PAPR and CAPR flyers, guides, videos, and checklists are provided, with additional materials to be added in the future. (Text)
08/01/2020 12:00 AM EDT
Source: United Nations Educational, Scientific and Cultural Organization (UNESCO). Published: 8/2020. This four-page document is aimed at national authorities responsible for the organization of tsunami warning and emergency response. It clarifies the status of the regional tsunami services for the Indian Ocean and suggests best practices for national and local actions during the COVID-19 pandemic. (PDF)
08/01/2020 12:00 AM EDT
Source: Harvard University. Published: 8/2020. This is a free data repository open to all researchers from any discipline, both inside and outside of the Harvard community, where they can share, archive, cite, access, and explore research data. Partnering with national health ministries and other government agencies in sub-Saharan Africa, South Asia, and Latin America, Population Council global and in-country scientists are conducting COVID-19 public health and social science research to produce relevant and timely evidence to support policymakers in controlling the spread of coronavirus, evaluating the effectiveness of prevention and mitigation measures, and assessing longer-term health, social, and economic effects of the pandemic. (Text)
08/01/2020 12:00 AM EDT
Source: HelpAge International. Published: 8/2020. This 15-page document discusses how providing psychosocial support during the different phases of the COVID-19 crisis can help people cope better, including older people, their caregivers, and their families. (PDF)
08/01/2020 12:00 AM EDT
Source: HelpAge International. Published: 8/2020. This web page provides country COVID-19 Rapid Needs Assessments that contain key findings, observations, and a detailed analysis of the many challenges older people face as a result of COVID-19. (Text)
08/01/2020 12:00 AM EDT
Source: National Academies of Sciences, Engineering, and Medicine. Published: 8/2020. This web page provides information and webinars from an ad hoc committee of the National Academies of Sciences, Engineering, and Medicine and the National Academy of Medicine, which will develop an overarching framework for vaccine allocation to assist policymakers in the domestic and global health communities in planning for equitable allocation of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). (Text)
08/01/2020 12:00 AM EDT
Source: National Association of County and City Health Officials (NACCHO). Published: 8/2020. This 147-page study summarizes the collection of data about local health department infrastructure and practice at the national level. It discusses how crises like the COVID-19 pandemic emphasize the need for timely information and data to support public health practice, especially at the local level, and how the pandemic has impacted local health departments. (PDF)
07/30/2020 12:00 AM EDT
Source: Dialogue4Health. Published: 7/30/2020. This one-hour, 27-minute Congressional briefing features presenters from Trust for America’s Health, American Public Health Association, NAACP, the National Black Nurses Association, the National Collaborative for Health Equity, and the National Medical Association, who discuss the disproportionate health and economic impacts of the COVID-19 pandemic on the Black community and other communities of color, and how structural racism drives systemic inequities in health, the economy, and criminal justice. (Video or Multimedia)
07/29/2020 12:00 AM EDT
Source: Henry J. Kaiser Family Foundation. Published: 7/29/2020. This review of the latest available data indicates that, while children who are infected with COVID-19 are more likely to be asymptomatic and less likely to experience severe disease (though a small subset become quite sick), they are capable of transmitting to both children and adults. (Text)
07/29/2020 12:00 AM EDT
Source: Mountain Plains Addiction Technology Transfer Center Network. Published: 7/29/2020. This one-hour, 14-minute webinar features speakers who provide information regarding the COVID-19 pandemic and HIPAA, 42 CFR Part 2, and the CARES Act as it relates to virtual services. Participants will be introduced to the tip sheets and technical assistance services provided by the Center of Excellence for Protected Health Information. (Video or Multimedia)
07/27/2020 12:00 AM EDT
Source: American Academy of Pediatrics (AAP). Published: 7/27/2020. This web page provides guidance during the COVID-19 pandemic for pediatricians and others who care for children in the child welfare system that affirms that a stable home and caregiver are important to nurturing a child’s development and preventing trauma that can affect a child across the lifespan. (Text)
07/23/2020 12:00 AM EDT
Source: Washington State Department of Health. Published: 7/23/2020. This eight-page report was a collaboration between Department of Health and Labor and Industries, Safety and Health Assessment and Research for Prevention Program, and contains data on occupation and industry among lab-confirmed cases of COVID-19 among Washington residents reported through June 16, 2020. (PDF)
07/22/2020 12:00 AM EDT
Source: American Academy of Pediatrics (AAP). Published: 7/22/2020. This web page provides new guidance for pediatricians to inform families on how to mitigate risk and prevent the spread of SARS-CoV-2 to others both within sport and within families and the community. (Text)
07/16/2020 12:00 AM EDT
Source: Alliance for Child Protection in Humanitarian Action. Published: 7/16/2020. This 15-page report presents a balanced analysis to inform decisions based on holistic child well-being as to when and why to reopen schools. This paper is meant to help decision-makers frame a holistic analysis of school closure on the well-being of children and young people, and to consider the safe reopening of schools. (PDF)
07/15/2020 12:00 AM EDT
Source: Government of Canada. Published: 7/15/2020. This web page provides recommendations that were developed to inform clinical trials of candidate COVID-19 vaccines to protect against infection, serious illness, and deaths caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). (Text)
07/01/2020 12:00 AM EDT
Source: World Health Organization, Pan American Health Organization (PAHO). Published: 7/2020. This five-page document offers an algorithm for the management of COVID-19 patients at the first level of care and in remote areas, with focus on early case identification-based on severity, and timely indications of remission. (PDF)
07/01/2020 12:00 AM EDT
Source: World Economic Forum. Published: 7/2020. This 31-page document is an update of the Early Compendium of Technology Responses to COVID-19 published in April 2020. It more than triples the number of solutions, providing better visibility into the diverse uses of technology for the COVID-19 response. (PDF)
07/01/2020 12:00 AM EDT
Source: University of Melbourne. Published: 7/2020. This web page provides links to two reports that detail tests to dry SARS-CoV-2 on untreated stainless steel and fabric surface, then to investigate whether wet contact with Bioprotect reagent will reduce virus infectivity; and to dry SARS-CoV-2 on pre-treated stainless steel and fabric surfaces and investigate whether the pre-treated surface maintains viricidal effectiveness. (PDF)
07/01/2020 12:00 AM EDT
Source: World Health Organization, Regional Office for Europe. Published: 7/2020. This two-page fact sheet details how people experiencing homelessness are particularly at risk during the COVID-19 pandemic, and lists measures that are required to protect people experiencing homelessness. (PDF)
06/10/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/10/2020. This web page is intended to address questions related to the design, evaluation, labeling, and marketing of hospital beds, stretchers, and mattresses during the COVID-19 public health emergency. (Text)
06/05/2020 12:00 AM EDT
Source: American Academy of Pediatrics (AAP). Published: 6/5/2020. This web page provides guidance for pediatricians and families as they make informed decisions on sending children to overnight/sleep away or day camp during the COVID-19 pandemic this summer. (Text)
06/01/2020 12:00 AM EDT
Source: United Nations Children's Fund (UNICEF). Published: 6/2020. The guidelines in this five-page document aim to inform the decision-making process regarding school reopening during the COVID-19 pandemic, support national preparations, and guide the implementation process, as part of overall public health and education planning processes. The document is co-published with UNESCO, the World Bank, World Food Programme, and United Nations High Commissioner for Refugees. It outlines six key priorities to assess the readiness of those schools and inform planning. (PDF)
06/01/2020 12:00 AM EDT
Source: World Health Organization, Regional Office for Europe. Published: 6/2020. This two-page fact sheet outlines key principles that underpin actions to address COVID-19 among people who use drugs (PWUD). The continuity and sustainability of treatment, health care, social protection, and rehabilitation services, including access to controlled drugs for medical purposes, must be ensured. Drug services need to remain tailored to the needs of vulnerable groups among PWUD, such as women; those who are lesbian, gay, bisexual, transgender, queer (LGBTQ); youth; and refugees. (PDF)
06/01/2020 12:00 AM EDT
Source: World Health Organization, Regional Office for Europe. Published: 6/2020. This two-page fact sheet details key principles for children and adolescents deprived of liberty in the context of the COVID-19 response in the WHO European Region. Any response should be consistent with best evidence and ensure that children are involved; basic human rights of children must not be breached; and isolation in response to COVID-19 should not be used as solitary confinement or punishment. (PDF)
06/01/2020 12:00 AM EDT
Source: World Health Organization, Regional Office for Europe. Published: 6/2020. This two-page fact sheet discusses how children and young people living in orphanages and other situations of mass accommodation, such as unaccompanied minors, are vulnerable to the spread of infection that might be introduced from outside, including COVID-19. While infection control measures will increase health protection, new vulnerabilities are created, as they usually result in more restrictions of freedom, contact, and social isolation. (PDF)
05/27/2020 12:00 AM EDT
Source: Child Care Aware of America. Published: 5/27/2020. This webinar discusses the five essential needs of children during disasters (including public health emergencies such as COVID-19) and gain practical tips to help children cope through play, and self expression activities. (Video or Multimedia)
05/01/2020 12:00 AM EDT
Source: United Nations (UN). Published: 5/2020. The guidelines in this eight-page document seek to address how to adapt regular municipal waste management services to a pandemic situation, and support decision-makers in developing a solid waste management response strategy to the COVID-19 situation. (PDF)
05/01/2020 12:00 AM EDT
Source: World Bank. Published: 5/2020. This four-page brief discusses how good and consistently applied WASH and waste management practices serve as essential barriers to human-to-human transmission of the COVID-19 virus in communities, homes, healthcare facilities, schools, and other public spaces. (PDF)
05/01/2020 12:00 AM EDT
Source: International Federation of Red Cross and Red Crescent Societies (IFRC). Published: 5/2020. This 48-page document provides guidance on suicide and harm prevention, tailored to the needs of National Societies. It offers resources relevant to those who may be implementing suicide prevention initiatives for the first time and to those who may be adapting existing activities around suicide and harm prevention to the specific challenges of COVID-19. (PDF)
04/29/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/29/2020. This web page provides answers to frequently asked questions about Emergency Use Authorizations (EUAs) and medical devices during the COVID-19 pandemic. (Text)
04/29/2020 12:00 AM EDT
Source: Bipartisan Policy Center. Published: 4/29/2020. This 22-page report summarizes a study to assess how countries around the world are attempting to relax social distancing interventions as they transition from the initial COVID-19 pandemic wave. (PDF)
04/18/2020 12:00 AM EDT
Source: Società Italiana di Anestesia, Analgesia, Rianimazione e Terapia Intensiva (SIAARTI). Published: 4/18/2020. This 24-page document is intended for all healthcare institutions that handle people with COVID-19, particularly those in an unstable clinical condition, and aims to help the care team in communicating with families living in complete isolation from the patient. (PDF)
04/13/2020 12:00 AM EDT
Source: Child Care Aware of America. Published: 4/13/2020. Speakers in this one-hour webinar discuss COVID-19 guidance from the CDC that provides details for child care providers and programs that choose to remain open, focusing on social distancing strategies, cleaning and disinfection efforts, modifying drop-off and pick-up procedures, caring for infants and toddlers, healthy hand hygiene behavior, food preparation and meal service, vulnerable and high-risk groups, and how best to maintain adequate rations of staff to children to ensure safety. (Video or Multimedia)
04/08/2020 12:00 AM EDT
Source: International Solid Waste Association (ISWA). Published: 4/8/2020. This 12-page document provides detailed recommendations for three overall priorities for waste management during the period of the COVID-19 pandemic. (PDF)
04/01/2020 12:00 AM EDT
Source: United Nations Children's Fund (UNICEF). Published: 4/2020. This 18-page paper identifies key ethical considerations when undertaking evidence generation involving children during the mitigation stage of the pandemic (emergency phase), on subject matter relating to COVID-19 once the pandemic has been contained, and once containment policy measures, including lockdowns, have been lifted (post-emergency phase). (PDF)
04/01/2020 12:00 AM EDT
Source: World Economic Forum. Published: 4/2020. This 13-page document is an initial collection of responses to the COVID-19 pandemic from leading global technology players. It includes 80 initial use cases representing 61 unique companies, across six main categories. (PDF)
03/01/2020 12:00 AM EST
Source: United Nations Children's Fund (UNICEF). Published: 3/2020. In the context of the COVID-19 pandemic, persons with disabilities may have increased risk for exposure, complications, and death. This five-page document details what we need to know about people with disabilities, and what we need to do to protect them. (PDF)
.png)
No hay comentarios:
Publicar un comentario